Showing results (1131-1140 of 1,142) with videos related to
Sort By:
Pageof 115
Nature Communications|November 11, 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencingGuan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, et al.The Lancet. Oncology|January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trialLei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II TrialLi Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.The Journal of Infectious Diseases|April 2, 2023
Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort StudyLin Tang, Fu-Zhen Wang, Lance E Rodewald, et al.European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancerRichard R Love, Syed Mozammel Hossain, Md Margub Hussain, et al.Nature Cancer|February 12, 2024
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilitiesYi-Zhou Jiang, Ding Ma, Xi Jin, et al.Chinese Medical Journal|November 30, 2020
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT studyBin Su, Cheng Yao, Qing-Xia Zhao, et al.Journal of Digestive Diseases|April 8, 2025
Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024)Yi Min Mao, Jie Ting Tang, Zhong Hua Lu, et al.The Lancet. Oncology|November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trialHuiping Li, Jieqiong Liu, Quchang Ouyang, et al.Blood Cancer Discovery|October 18, 2021
Hyperthermia Selectively Destabilizes Oncogenic Fusion ProteinsYasen Maimaitiyiming, Qian Qian Wang, Chang Yang, et al.Pageof 115